Clinical Trial Update: A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B [Phase 1]

View source ↗

Summary

A Phase 1 trial of GS-9620 (vesatolimod) in treatment-naive subjects with chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GS-9620 (vesatolimod) (vesatolimod)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis B, HBV | Phase 1 | Status: COMPLETED